Table 5.
Adjusted1 hazard ratios for disease-specific and recurrence free survival.2
| Risk Factors | Oral cavity | Oropharynx | ||||||
|---|---|---|---|---|---|---|---|---|
| Disease-specific Survival1 | Recurrence-free survival1 | Disease-specific survival1 | Recurrence-free survival1 | |||||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Patients with HPV serology (N = 182) | ||||||||
| N = 116 | N = 96 | N = 52 | N = 43 | |||||
| E6 and/or E7 | n | n | n | n | ||||
| Negative | 103 (88.8) | 1.3 (0.4–4.2) | 86 (89.6) | 1.1 (0.3–3.6) | 16 (30.8) | 5.7 (1.7–20.0) | 13 (30.2) | 6.7 (1.7–26.1) |
| Positive | 13 (11.2) | 1.0 | 10 (10.4) | 1.0 | 36 (69.2) | 1.0 | 30 (69.8) | 1.0 |
| Age2 | 1.02 (1.0–1.1) | 1.02 (1.0–1.04) | 1.04 (0.96–1.1) | 1.03 (0.95–1.1) | ||||
| Stage | ||||||||
| 0/I/II | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| III/IV | 7.9 (2.8–22.5) | 1.5 (0.7–3.1) | 1.5 (0.2–11.4) 3 | 1.3 (0.03–58.8) | ||||
|
| ||||||||
| Patients with both HPV tumor and serology (N = 157) | ||||||||
| N = 100 | N = 88 | N = 44 | N = 39 | |||||
|
| ||||||||
| E6 and/or E7 | n | n | n | n | ||||
| Negative | 89 (89.0) | 1.4 (0.4–4.5) | 80 (90.9) | 1.1 (0.3–3.5) | 14 (31.8) | 4.2 (1.2–15.1) | 12 (30.8) | 10.4 (2.4–52.4) |
| Positive | 11 (11.0) | 1.0 | 8 (9.1) | 1.0 | 30 (68.2) | 1.0 | 27 (69.2) | 1.0 |
| HPV tumor status | ||||||||
| Negative | 88 (88.0) | 0.8 (0.3–2.0) | 78 (88.6) | 0.5 (0.2–1.3) | 17 (38.6) | 3.0 (0.9–10.7) | 15 (38.5) | 7.3 (1.5–36.4) |
| High Risk | 12 (12.0) | 1.0 | 10 (11.4) | 1.0 | 27 (61.4) | 1.0 | 24 (61.5) | 1.0 |
1Adjusted for stage and continuous age; 2in years; 3odds ratio Logit estimator adjusted for stage and categorical age.